Identification and characterization of a novel endogenous murine parkin mutation

Journal of Neurochemistry

Volumn 113, Issue 2, 2010, Pages 402-417

  Ramsey, Chenere P ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

C3H mouse; E3 ligase; Mutation; Parkin; Parkinson's disease; Recessive

Indexed keywords

BRAIN EXTRACT; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PRK109; MONOCLONAL ANTIBODY PRK28; MONOCLONAL ANTIBODY PRK8; PARKIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN CONJUGATING ENZYME E2 UBCH7; UBIQUITIN CONJUGATING ENZYME E2 UBCH8; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOREACTIVITY; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BRAIN; CARRIER PROTEINS; CELL LINE; DNA MUTATIONAL ANALYSIS; EPITOPE MAPPING; GENE EXPRESSION REGULATION; GLUTAMIC ACID; GLUTAMINE; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, INBRED STRAINS; MUTATION; NERVE TISSUE PROTEINS; RNA, MESSENGER; SPECIES SPECIFICITY; TRANSFECTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

MURINAE; MUS;

EID: 77949747845     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06605.x     Document Type: Article

References (72)

1. Asakawa S., Tsunematsu K., Takayanagi A. et al. (2001) The genomic structure and promoter region of the human parkin gene. Biochem. Biophys. Res. Commun. 286, 863 868.
2. Bardien S., Keyser R., Yako Y., Lombard D. Carr J. (2009) Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease. Parkinsonism Relat. Disord. 15, 116 121.
3. Bonifati V. (2007) Genetics of parkinsonism. Parkinsonism Relat. Disord. 13 (Suppl. 3 S233 S241.
4. Cairns N. J., Uryu K., Bigio E. H. et al. (2004) Alpha-internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol. 108, 213 223.
5. Choi P., Ostrerova-Golts N., Sparkman D., Cochran E., Lee J. M. Wolozin B. (2000) Parkin is metabolized by the ubiquitin/proteosome system. Neuroreport 11, 2635 2638.
6. Choi P., Snyder H., Petrucelli L. et al. (2003) SEPT5-v2 is a parkin-binding protein. Brain Res. Mol. Brain Res. 117, 179 189.
7. Chung K. K., Zhang Y., Lim K. L., Tanaka Y., Huang H., Gao J., Ross C. A., Dawson V. L. Dawson T. M. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin- 1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7, 1144 1150.
8. Chung K. K., Thomas B., Li X., Pletnikova O., Troncoso J. C., Marsh L., Dawson V. L. Dawson T. M. (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304, 1328 1331.
9. Ciechanover A. (2001) Linking ubiquitin, parkin and synphilin-1. Nat. Med. 7, 1108 1109.
10. von Coelln R., Dawson V. L. Dawson T. M. (2004a) Parkin-associated Parkinson's disease. Cell Tissue Res. 318, 175 184.
11. von Coelln R., Thomas B., Savitt J. M., Lim K. L., Sasaki M., Hess E. J., Dawson V. L. Dawson T. M. (2004b) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl Acad. Sci. USA 101, 10744 10749.
12. von Coelln R., Thomas B., Andrabi S. A. et al. (2006) Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. J. Neurosci. 26, 3685 3696.
13. Corti O., Hampe C., Koutnikova H. et al. (2003) The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet. 12, 1427 1437.
14. Dodson M. W. Guo M. (2007) Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr. Opin. Neurobiol. 17, 331 337.
15. Fitzgerald J. C. Plun-Favreau H. (2008) Emerging pathways in genetic Parkinson's disease: autosomal-recessive genes in Parkinson's disease - a common pathway? FEBS J. 275, 5758 5766.
16. Fournier M., Vitte J., Garrigue J. et al. (2009) Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS ONE 4, e6629.
17. Frank-Cannon T. C., Tran T., Ruhn K. A. et al. (2008) Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 28, 10825 10834.
18. Gallagher M. J., Huang H., Grant E. R. Lynch D. R. (1997) The NR2B-specific interactions of polyamines and protons with the N-methyl-D-aspartate receptor. J. Biol. Chem. 272, 24971 24979.
19. Goldberg M. S., Fleming S. M., Palacino J. J. et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628 43635.
20. Gu W. J., Corti O., Araujo F. et al. (2003) The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol. Dis. 14, 357 364.
21. Guo J. F., Xiao B., Liao B. et al. (2008) Mutation analysis of Parkin, PINK1, DJ-1 and ATP13A2 genes in Chinese patients with autosomal recessive early-onset Parkinsonism. Mov. Disord. 23, 2074 2079.
22. Hampe C., Ardila-Osorio H., Fournier M., Brice A. Corti O. (2006) Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet. 13, 2059 2075.
23. Hedrich K., Eskelson C., Wilmot B. et al. (2004) Distribution, type, and origin of Parkin mutations: review and case studies. Mov. Disord. 19, 1146 1157.
24. Henn I. H., Bouman L., Schlehe J. S. et al. (2007) Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 27, 1868 1878.
25. Huynh D. P., Scoles D. R., Nguyen D. Pulst S. M. (2003) The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum. Mol. Genet. 12, 2587 2597.
26. Imai Y., Soda M. Takahashi R. (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35661 35664.
27. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. Takahashi R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891 902.
28. Itier J. M., Ibanez P., Mena M. A. et al. (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12, 2277 2291.
29. Joazeiro C. A. Weissman A. M. (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell 102, 549 552.
30. Kao S. Y. (2009) Regulation of DNA repair by parkin. Biochem. Biophys. Res. Commun. 382, 321 325.
31. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605 608.
32. Kitada T., Asakawa S., Matsumine H., Hattori N., Minoshima S., Shimizu N. Mizuno Y. (1999) Positional cloning of the autosomal recessive juvenile parkinsonism (AR-JP) gene and its diversity in deletion mutations. Parkinsonism Relat Disord 5, 163 168.
33. Kitada T., Asakawa S., Minoshima S., Mizuno Y. Shimizu N. (2000) Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm. Genome 11, 417 421.
34. Kitao Y., Imai Y., Ozawa K. et al. (2007) Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum. Mol. Genet. 16, 50 60.
35. Ko H. S., von Coelln R., Sriram S. R. et al. (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25, 7968 7978.
36. Ko H. S., Kim S. W., Sriram S. R., Dawson V. L. Dawson T. M. (2006) Identification of far up stream element binding protein-1 as an authentic parkin substrate. J. Biol. Chem. 281, 16193 16196.
37. LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G. Selkoe D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214 1221.
38. LaVoie M. J., Cortese G. P., Ostaszewski B. L. Schlossmacher M. G. (2007) The effects of oxidative stress on parkin and other E3 ligases. J. Neurochem. 103, 2354 2368.
39. Li H. Guo M. (2009) Protein degradation in Parkinson disease revisited: it's complex. J. Clin. Invest. 119, 442 445.
40. Lim K. L., Chew K. C., Tan J. M. et al. (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 25, 2002 2009.
41. Lucking C. B., Durr A., Bonifati V. et al. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342, 1560 1567.
42. Macedo M. G., Verbaan D., Fang Y. et al. (2009) Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. Mov. Disord. 24, 196 203.
43. Marin I., Lucas J. I., Gradilla A. C. Ferrus A. (2004) Parkin and relatives: the RBR family of ubiquitin ligases. Physiol. Genomics 17, 253 263.
44. Mata I. F., Lockhart P. J. Farrer M. J. (2004) Parkin genetics: one model for Parkinson's disease. Hum. Mol. Genet. 13 (Spec No 1 R127 R133.
45. Moore D. J., West A. B., Dikeman D. A., Dawson V. L. Dawson T. M. (2008) Parkin mediates the degradation-independent ubiquitination of Hsp70. J. Neurochem. 105, 1806 1819.
46. Morett E. Bork P. (1999) A novel transactivation domain in parkin. Trends Biochem. Sci. 24, 229 231.
47. Murray I. J., Medford M. A., Guan H. P., Rueter S. M., Trojanowski J. Q. Lee V. M. (2003) Synphilin in normal human brains and in synucleinopathies: studies with new antibodies. Acta Neuropathol. (Berl) 105, 177 184.
48. Palacino J. J., Sagi D., Goldberg M. S., Krauss S., Motz C., Wacker M., Klose J. Shen J. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614 18622.
49. Pawlyk A. C., Giasson B. I., Sampathu D. M. et al. (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem. 278, 48120 48128.
50. Perez F. A. Palmiter R. D. (2005) Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl Acad. Sci. USA 102, 2174 2179.
51. Perez F. A., Curtis W. R. Palmiter R. D. (2005) Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci. 6, 71.
52. Periquet M., Latouche M., Lohmann E. et al. (2003) Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 126, 1271 1278.
53. Poorkaj P., Nutt J. G., James D., Gancher S., Bird T. D., Steinbart E., Schellenberg G. D. Payami H. (2004) parkin mutation analysis in clinic patients with early-onset Parkinson disease. Am. J. Med. Genet. A 129A, 44 50.
54. Rankin C. A., Joazeiro C. A., Floor E. Hunter T. (2001) E3 ubiquitin-protein ligase activity of Parkin is dependent on cooperative interaction of RING finger (TRIAD) elements. J. Biomed. Sci. 8, 421 429.
55. Ren Y., Zhao J. Feng J. (2003) Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J. Neurosci. 23, 3316 3324.
56. Sato S., Chiba T., Nishiyama S. et al. (2006) Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography. J. Neurosci. Res. 84, 1350 1357.
57. Shimura H., Hattori N., Kubo S. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302 305.
58. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S. Selkoe D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263 269.
59. Sriram S. R., Li X., Ko H. S., Chung K. K., Wong E., Lim K. L., Dawson V. L. Dawson T. M. (2005) Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 14, 2571 2586.
60. Staropoli J. F., McDermott C., Martinat C., Schulman B., Demireva E. Abeliovich A. (2003) Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37, 735 749.
61. Sun M., Latourelle J. C., Wooten G. F. et al. (2006) Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch. Neurol. 63, 826 832.
62. Tan E. K. Skipper L. M. (2007) Pathogenic mutations in Parkinson disease. Hum. Mutat. 28, 641 653.
63. Tanaka K., Suzuki T., Hattori N. Mizuno Y. (2004) Ubiquitin, proteasome and parkin. Biochim. Biophys. Acta 1695, 235 247.
64. Thomas B., von Coelln R., Mandir A. S. et al. (2007) MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol. Dis. 26, 312 322.
65. Um J. W., Min D. S., Rhim H., Kim J., Paik S. R. Chung K. C. (2006) Parkin ubiquitinates and promotes the degradation of RanBP2. J. Biol. Chem. 281, 3595 3603.
66. Ved R., Saha S., Westlund B. et al. (2005) Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280, 42655 42668.
67. Wang C., Ko H. S., Thomas B. et al. (2005a) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 14, 3885 3897.
68. Wang C., Tan J. M., Ho M. W. et al. (2005b) Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J. Neurochem. 93, 422 431.
69. Winklhofer K. F., Henn I. H., Kay-Jackson P. C., Heller U. Tatzelt J. (2003) Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J. Biol. Chem. 278, 47199 47208.
70. Wu R. M., Bounds R., Lincoln S., Hulihan M., Lin C. H., Hwu W. L., Chen J., Gwinn-Hardy K. Farrer M. (2005) Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. Arch. Neurol. 62, 82 87.
71. Zhang Y., Gao J., Chung K. K., Huang H., Dawson V. L. Dawson T. M. (2000) Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA 97, 13354 13359.
72. Zhu X. R., Maskri L., Herold C., Bader V., Stichel C. C., Gunturkun O. Lubbert H. (2007) Non-motor behavioural impairments in parkin-deficient mice. Eur. J. Neurosci. 26, 1902 1911.